Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease Within Subject Crossover Study of Cognitive Effects of Neflamapimodin Early-Stage Huntington Disease ...
A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Co ...
Study of Neflamapimod in Early-Stage Huntington Disease (HD)
A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Cognitive Effects Of Neflamapimod in Early-Stage Huntington Disease (HD) A Double-Blind, Placebo-Controlled Two-Period 10-Week Treatment Within-Subject Crossover Study Of Co ...
Early-Stage Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Early-Stage Huntington Disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Hun ...
Product Name: Neflamapimod Product Code: VX-745 INN or Proposed INN: Neflamapimod Other descriptive name: VX-745 Product Name: Neflamapimod Product Code: VX-745 INN or Proposed INN: Neflamapimod Other descriptive nam ...
EIP Pharma, Inc.
NULL
Authorised-recruitment may be ongoing or finished
Female: yes Male: yes
16
Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...